Overview

D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia

Status:
Unknown status

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This study aims at exploring the activity of a frontline approach based on dasatinib plus steroids administration as induction treatment, followed by the infusion of Blinatumomab, in adult Ph+ ALL.

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Italiano Malattie EMatologiche dell'Adulto

Treatments:

Antibodies, Bispecific
Blinatumomab
Dasatinib